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ORIGINAL ARTICLE
Introduction: We investigated the ability of cell-free microRNAs 
(miRNAs) in plasma and serum to serve as a biomarker for malig-
nant mesothelioma (MM).
Methods: Using miRNA microarrays, we profiled plasma samples 
from MM patients and healthy controls. miRNAs with significantly 
different abundance between cases and controls were validated in a 
larger series of MM patients and in an independent series of MM 
patients using quantitative real-time polymerase chain reaction. 
Levels of candidate miRNAs were also quantified in MM tumor 
samples.
Results: We compared cell-free miRNA profiles in plasma from 
MM patients with healthy controls. Reviewing 90 miRNAs previ-
ously reported to be associated with MM, we found that the levels of 
two miRNAs, miR-29c* and miR-92a, were elevated in plasma sam-
ples from MM patients. In addition, we identified 15 novel miRNAs 
present at significantly higher levels in the plasma of MM patients. 
Further analysis of candidate miRNAs by real time-quantitative 
polymerase chain reaction confirmed that one of them, miR-625-3p, 
was present in significantly higher concentration in plasma/serum 
from MM patients and was able to discriminate between cases and 
controls, in both the original and the independent series of patients. 
MiR-625-3p was also found to be up-regulated in tumor speci-
mens from a group of 18 MM patients, who underwent extrapleural 
pneumonectomy.
Conclusion: Our data confirm the potential of miR-29c* and miR-
92a as candidate tumor markers and reveal that miR-625-3p is a 
promising novel diagnostic marker for MM.
Key Words: Mesothelioma, MicroRNA, Plasma, Biomarker, Diagnosis. 
(J of Thorac Oncol. 2012;7: 1184–1191)
Maligant mesothelioma (MM) is a highly aggressive tumor arising from the mesothelial surfaces of the pleu-
ral and peritoneal cavities. The global burden of this neoplasm 
that in most cases has direct causal relationship with exposure 
to asbestos has increased significantly in the last two decades 
and is still on the rise.1,2 The diagnosis of tumors arising in 
the pleura or peritoneum is difficult,3,4 and the accuracy of the 
MM diagnosis depends on the availability of sufficient biopsy 
material. Some centers use cytological analysis of pleural fluid 
for differential diagnosis but this approach has not received 
universal acceptance.4 Finding a reliable diagnostic marker in 
plasma or serum would represent a significant advancement 
and might at the same time provide the opportunity for detect-
ing the disease at an earlier stage. Although the application of 
new molecular biological techniques has led to the identifica-
tion of serum proteins associated with the presence of MM, 
markers such as mesothelin, megakaryocyte potentiating fac-
tor, and osteopontin have failed to achieve the specificity and 
sensitivity required for an accurate diagnosis.5–8
MicroRNAs (miRNAs) are a class of short (~25 
nucleotides) noncoding RNAs that regulate gene expression 
post-transcriptionally through sequence-specific interaction 
with target sites in messenger RNAs.9 Characteristic alterations 
in miRNA expression profiles have been found in a number 
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of tumor types,10 including MM. Their stability in archival 
tumor blocks and body fluids such as serum and plasma11,12 
makes them attractive candidate biomarkers. Elevated 
plasma miRNA levels have been reported in patients with 
diffuse large B-cell lymphoma,13 ovarian cancer,14 colorectal 
cancer,15,16 prostate cancer12, and lung cancer.11 Other studies 
have revealed an association between reduced serum levels of 
particular miRNAs and the presence of a tumor.17
In this study, we have used microarrays to compare the 
plasma miRNA profiles of MM patients with control subjects. 
After reverse transcription-quantitative polymerase chain 
reaction (RT-qPCR) validation in two independent series 
of patients, miR-625-3p was found to be present at signifi-
cantly higher levels in plasma/serum of MM patients, and this 
miRNA was also present at elevated levels in tumor samples.
MATERIALS AND METHODS
Blood Collection and Preparation of Plasma 
and Serum
Plasma of the test cohort was collected in 10 ml Vacutainer 
Plus K
3
ethylenediaminetetraacetic acid tubes (BD Biosciences, 
Franklin Lakes, NJ). Samples from MM patients or control 
subjects (patients with coronary artery disease or healthy sub-
jects) were collected before treatment (Table 1 with details pro-
vided in Supplementary Table 1, Supplemental Digital Content 
1, http://links.lww.com/JTO/A284). Within 30 minutes of col-
lection, the tubes were centrifuged for 20 minutes at 2500 g at 
room temperature. Levels of free hemoglobin were measured 
by spectral analysis as previously described,18 and samples with 
hemoglobin levels corresponding to an A414 reading of greater 
than 0.25 were excluded from analyses. Plasma was stored at 
−80°C until further processing. All samples were collected 
from individuals who had given written informed consent 
and participated in studies approved by the Human Research 
Ethics Committees at Concord Repatriation General Hospital 
and Royal Prince Alfred Hospital (RPAH), Sydney, New South 
Wales, Australia. Sera of the validation cohort (Table 1 with 
details provided in Supplementary Table 1, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A284) were col-
lected from patients presenting with symptoms at the respi-
ratory clinics of either Sir Charles Gairdner Hospital or the 
Hollywood Specialist Centre in Perth, Western Australia (WA). 
The serum samples form part of the Australian Mesothelioma 
Tissue Bank, a member bank of the Australasian Biospecimen 
Network, which is supported in part by the Australian National 
Health and Medical Research Council and the National Centre 
for Asbestos-Related Diseases. Blood samples collected by 
routine venipuncture were stored in BD Vacutainer serum 
tubes (BD Bioscience). Serum samples were allowed to clot 
at room temperature for at least 2 hours, or at 4°C overnight, 
before processing. Samples were centrifuged at 1200 rpm for 
10 minutes, and then the supernatant was removed, aliquoted, 
and stored at −80°C until assay. Written informed consent was 
obtained from all participants. This study was approved by the 
Human Research Ethics Committees of Sir Charles Gairdner 
Hospital and Hollywood Specialist Centre.
Tumor and Pericardial Tissue Samples
The tumor samples used in this study were part of a 
previously reported series of samples from MM patients 
who underwent extrapleural pneumonectomy between 1994 
and 2009 at RPAH or Strathfield Private Hospital, Sydney, 
Australia.19 The specimens were all formalin-fixed paraf-
fin-embedded (FFPE) tumor blocks (Table 2, with details 
provided in Supplementary Table 1, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A284). The tumor con-
tent was marked on whole sections to guide laser-capture 
microdissection. This work was conducted as part of a larger 
study aimed at identifying prognostic factors in MM, and 
was approved by the Human Research Ethics Committee at 
Concord Repatriation General Hospital, Sydney. Normal peri-
cardial tissue was collected from consenting patients with-
out history of cancer, undergoing cardiac or aortic surgery at 
RPAH (Table 2, with details provided in Supplementary Table 
1, Supplemental Digital Content 1, http://links.lww.com/JTO/
A284). The tissues were fixed in formalin. All pericardial sam-
ples were collected as part of a study approved by the Human 
Research Ethics Committee at RPAH, Sydney, Australia.
TABLE 1.  Demographic and Pathological Characteristics  
of Study Patients (Plasma/Serum)
Test Cohort Validation Cohort
MM  
(N = 15)
Control  
(N = 14)
MM  
(N = 30)
Asbestosis  
(N = 10)
Median age 
(range)
68 (51–83) 58.5 (21–78) 72.5 (47–86) 70.5 (67–86)
Sex
 Male 13 9 30 10
 Female 2 5 0 0
Histotype
 Epithelioid 
(%)
9 (60) — 29 (96.66) —
 Biphasic 
(%)
3 (20) — 0 —
 Sarcoma-
toid (%)
2 (13.33) — 0 —
 Unspeci-
fied (%)
1 (0.07) — 1 (0.33) —
MM, malignant mesothelioma.
TABLE 2.  Demographic and Pathological Characteristics  
of Study Patients (Tissue Samples)
MM (N = 18) Control (N = 7)
Median age (range) 55 (37–66) 68 (57–76)
Sex
 Male 14 5
 Female 4 2
Histotype
 Epithelioid 15 (83.33 %) —
 Biphasic 3 (16.66 %) —
 Sarcomatoid 0 —
MM, malignant mesothelioma.
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RNA Isolation
Total RNA was isolated from plasma using the mirVana 
PARIS miRNA isolation kit (Ambion/Applied Biosystems, 
Foster City, CA) according to the manufacturer’s instructions 
for isolation of total RNA, with modifications as previously 
described.18 RNA from microdissected FFPE tumor samples 
or formalin-fixed pericardium was isolated using the miR-
Neasy FFPE extraction kit (Qiagen, Valencia, CA) following 
the manufacturer’s instructions. All RNAs were quantified 
using a Nanophotometer (Implen, Munich, Germany) with 
readings at 260 and 280 nm. RNA samples were stored at 
−80°C until further processing.
Microarray Analysis
The miRNA content in plasma from five patients with 
MM and from three healthy controls was profiled using the 
Human 8x15K miRNA Microarray Kit (V3, miRBase V12.0, 
Agilent Technologies, Santa Clara, CA). RNA (77 ng per sam-
ple) was labeled following the manufacturer’s instructions, 
and hybridized to the array slide for 21.5 hours. After wash-
ing, the array slide was stored in N
2
 gas for scanning within 
24 hours. The slide was scanned at the Ramaciotti Centre for 
Gene Function Analysis, UNSW, Sydney, using an Agilent 
Microarray Scanner (Agilent Technologies, Santa Clara, 
CA). Data were extracted using Agilent Feature Extraction 
FE10.5 software and then analyzed for differential expres-
sion of miRNAs using GeneSpringGX 11.0 software (Agilent 
Technologies). Data processing was performed applying 
thresholding of the signal values to 1, followed by normaliza-
tion to the 75th percentile without baseline transformation.
Real-Time RT-qPCR
Quantification of miRNA content in RNA from plasma 
of the test cohort was performed using stem-loop primers for 
reverse transcription and TaqMan primers/probes specific for 
each miRNA (Applied Biosystems, see Supplemental Data 
Table 2, Supplemental Digital Content 2, http://links.lww.com/
JTO/A285, for TaqMan Assay IDs). For reverse transcription 
we used the TaqMan MicroRNA Reverse Transcription Kit 
(Applied Biosystems) with the following reaction conditions: 
30 minutes at 16°C, followed by 30 minutes at 42°C, and 5 
minutes at 85°C. For plasma samples the reaction was carried 
out in a total reaction volume of 5 µl with a fixed volume of 
1.67 µl isolated RNA as template, whereas for FFPE samples, 
100 ng total RNA was reverse transcribed in a total reaction 
volume of 10 µl. All complementary DNA was used imme-
diately in qPCR reactions or stored at −20°C for use within 
1 week.
After reverse transcription, as recommended by the 
manufacturer, the complementary DNA was further diluted 
by addition of 28.9 µl or 57.8 µl H
2
O, respectively, to achieve 
a final dilution of 1:15 of the RT product. From the diluted RT 
product, 2.25 µl was used as template in a triplicate qPCR with 
a total reaction volume of 10 µl. Amplification was performed 
using miRNA TaqMan primers/probes specific for each 
miRNA together with TaqMan 2x Universal PCR MasterMix, 
No AmpErase UNG (Applied Biosystems) with enzyme acti-
vation for 10 minutes at 95°C followed by 40 cycles of 15 sec 
at 95°C and 60 sec at 60°C. No-template and no-RT samples 
were included as negative controls. The qPCR reactions were 
set up manually and run on a Stratagene Mx3000P instrument. 
C
q
 (quantification cycle) values were determined using adap-
tive-baseline and background-based threshold (cycle range, 
5–8) using the MxPro Mx3000P v4.10 software (Stratagene/
Agilent Technologies).
As we have shown previously that miR-16 levels vary 
little between patient and control plasma,18 this miR was used 
as endogenous reference for data normalization. miR-16 Cq 
values ranged from 19.54 to 21.72 with a standard deviation 
of 0.66. Relative expression levels of candidate miRNAs were 
calculated using the 2−ΔΔCq method20 with normalization to 
miR-16 (plasma/serum) or RNU6B (FFPE) as endogenous 
control, respectively, and calculation of relative expression 
as compared with the average ΔCq of the respective control 
samples.
OpenArray Analysis
Quantification of miRNAs in serum samples from the 
validation cohort was performed on the OpenArray platform 
(Applied Biosystems) following the manufacturer’s instruc-
tions. Briefly, for each sample two RT reactions with 3 µl or 
a maximum of 100 ng input RNA were performed using the 
MegaPlex RT primer pools A and B (Applied Biosystems). 
The RT reactions were performed on a StepONE PLUS real-
time thermocycler (LifeTechnologies) for 40 cycles of 2 min-
utes at 16°C, 1 minute at 42°C, and 1 second at 50°C, followed 
by 5 minutes at 85°C. The entire RT reaction was then used 
to perform the preamplification reaction using the MegaPlex 
preamp primer Pools A and B together with MegaPlex preamp 
Master Mix (Applied Biosystems). The preamplification reac-
tions were performed on the StepONE PLUS thermocycler 
under the following conditions: 10 minutes at 95°C, 2 minutes 
at 55°C, 2 minutes at 72°C, followed by 16 cycles of 15 sec-
onds at 95°C, and 4 minutes at 60°C. Preamplification reac-
tions were then incubated at 99.9°C for 10 minutes and cooled 
to 4°C. The samples were then frozen at –20°C overnight. The 
preamplification reactions were combined with the OpenArray 
real-time PCR Master Mix and loaded on to the OpenArray 
miRNA panel plates (Applied Biosystems) using the AccuFill 
autoloader. The loaded OpenArray plates were run on the 
OpenArray real-time PCR instrument (at the LotteryWest 
State Biomedical Facility Genomics, Royal Perth Hospital, 
WA) using the default protocol for reaction conditions.
Statistical Analysis
Differences in relative expression levels were analyzed 
using two-tailed Student’s t test. Receiver operating character-
istic curve of relative expression levels for hsa-miR-625-3p 
was plotted to assess the diagnostic value of plasma miRNAs 
to differentiate between patients and controls. Sensitivity and 
specificity were determined using the 75th percentile of the 
control group values (relative miRNA expression of 2.19) of 
the test cohort as cutoff. p values are unadjusted and a value of 
less than or equal to 0.05 was considered significant. Analyses 
were conducted using Predictive Analysis Software (version 
8; SPSS Inc., Chicago, IL).
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FIGURE 1. Microarray analysis of plasma from MM patients and controls. A, Relative expression of miRNAs in plasma from 
mesothelioma patients and healthy controls. Unsupervised clustering of the relative expression of 854 miRNAs detected on 
Agilent 8x15k microRNA microarrays in plasma from three healthy controls and five MM patients. The most abundant miR-
NAs detected on the array were present at similar levels in each sample. Most of the variation between samples was detected 
in those miRNAs present at low levels. B, Presence/absence of 90 MM-associated miRNAs as plotted as relative intensities per 
sample. Relative miRNA expression levels were divided into six categories depicting absence (green) or different expression 
levels (yellow = low expression and red = high expression). Those miRNAs previously associated with MM 23–30 and found at 
statistically significant elevated levels the plasma of mesothelioma patients in this study are highlighted in bold. Two-tailed t test 
p values were calculated on miR-16 normalized expression levels. MM, Maligant mesothelioma; miRNA, MicroRNAs. 
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RESULTS
Analysis of Plasma miRNA Profiles  
in MM Patients and Controls
In our search to identify new markers for MM, we used 
microarrays to profile the miRNA content of plasma from 
5 MM patients (three epithelioid [MM one, two, and eight], 
two sarcomatoid [MM four and five], see Supplementary 
Table 1, Supplemental Digital Content 1, http://links.lww.
com/JTO/A284, for details) and three healthy controls (N1-3). 
Unsupervised hierarchical clustering (euclidian and centroid 
linkage) of the processed intensity values (background cor-
rected, normalized by shift to 75th percentile without base-
line transformation) confirmed previous observations that the 
majority of miRNA species were present at similar levels in the 
plasma of patients and controls, and this included the common 
reference miRNA miR-16 (Fig. 1A).11,21,22 To compensate for 
differences in the quantities of miRNA isolated from plasma, 
we normalized the processed intensity data to the miR-16 levels 
in each sample, and then compared normalized levels of miR-
NAs of MM patients with that of controls. In this way, we identi-
fied 15 miRNAs present at significantly higher levels in patients 
(Table 3). We further analyzed levels of all 90 miRNAs previ-
ously reported to be associated with MM.23–30 Of these, 24 were 
detected in all samples, 36 were undetectable, and the remaining 
30 were detected in one to seven samples (Fig. 1B). Only three 
miRNAs previously found to be associated with MM, miR-
29c* 29, miR-92a,23 and miR-196b,23 were significantly higher 
in plasma of patients when compared with controls.
RT-qPCR Validation of miRNA Candidates
To validate miRNA candidates identified in the micro-
array analysis, the 12 miRNAs with the most significant ele-
vation levels in the plasma of MM patients were assessed in 
plasma from a series of 15 MM patients and 14 controls (Table 
1) using TaqMan assay-based real-time RT-qPCR. After nor-
malization to miR-16, the levels of miR-625-3p were 3.8-fold 
higher in MM patients when compared with controls (p = 
0.004, Fig. 2A). Levels of miR-29c* and miR-92a were 1.64- 
and 1.25-fold higher, respectively, without reaching signifi-
cance (Fig 2A, p = 0.098 and p = 0.147), whereas levels of the 
9 other miRNA candidates were not different between cases 
and controls (miR-26a-2-3p, -196b, -454-5p, and -1914-3p, 
data not shown) or were below the limits of detection (miR-
186-3p, -520a-3p, 548-3p, 767-3p, and -575, data not shown). 
Receiver operating characteristics curve analysis showed that 
plasma miR-625-3p levels discriminated between patient and 
control plasma with an accuracy of 82.4 % (area under the 
curve, 0.824; confidence interval, 0.669–0.979), a sensitivity 
of 73.33 % and a specificity of 78.57 % (Fig. 2B). Logistic 
regression was used to investigate the performance of com-
binations of the three miRs in terms of accuracy; however, 
miR-625-3p on its own provided the best and most simple 
classification (data not shown).
After confirmation in the test cohort, we compared 
miR-625-3p levels in an independent validation cohort 
consisting of serum from 10 patients with asbestosis and 
30 with MM from WA (Table 1) using the RT-qPCR-based 
OpenArray platform. Data from this cohort showed that 
miR-625-3p level was significantly elevated in serum from 
MM patients compared with asbestosis patients (Fig. 2C, 
p = 0.023), with an accuracy of 79.3% (area under the curve, 
0.793; confidence interval, 0.657–0.930), a sensitivity of 
70%, and a specificity of 90% (Fig. 2D).
Analysis of miRNAs in MM Tumors
The miRNAs present at higher levels in plasma of MM 
patients were further analyzed in RNA isolated from 18 archi-
val MM tumor blocks. RNA extracted from seven pericardial 
tissue samples served as control. For miR-625-3p, the average 
increase in tumor compared with normal mesothelium was 
4.35-fold (p = 0.012), with a greater than twofold increase in 
14 tumor samples (Fig. 3). Although the levels of the previ-
ously identified MM-associated miRNA, miR-29c*, showed 
a trend toward an increase in patient plasma, this miR was 
down-regulated twofold or more in 15 of 18 tumor specimens 
(average-fold decrease of –2.65; p = 0.005). Levels of miR-
16, present at very similar levels in the plasma of patients 
and controls, were strongly down-regulated by −36.7-fold (p 
= 0.008) in all tumors (Fig. 3). The level of miR-92a, which 
tended to increase in patient plasma, was elevated in only one 
sample, whereas it was either unchanged or decreased (aver-
age −1.8-fold, p = 0.082) in the remaining tumors (Fig. 3). The 
other miRNAs tested all showed lower expression in tumors 
(Fig. 3), with miR-196b (−3.78-fold, p = 0.014), miR-26a-
2-3p (−4.53-fold, p = 0.014), and miR-1914-3p (−2.22-fold, 
p = 0.021) being expressed significantly lower than in pericar-
dium, whereas the −3.42-fold lower level of miR-575 was not 
significantly (p = 0.174) different from the levels in normal 
tissue.
TABLE 3. Significantly Different miRNAs Detected by 
Microarray
N1 N2 N3 MM1 MM2 MM4 MM5 MM8 p Value
hsa-miR-186-3p 0.00 0.00 0.00 0.10 0.12 0.08 0.06 0.13 0.002
hsa-miR-520a-3p 0.05 0.04 0.04 0.14 0.16 0.16 0.21 0.11 0.002
hsa-miR-625-3p 0.22 0.22 0.21 0.25 0.27 0.27 0.28 0.24 0.002
hsa-miR-26a-2-3p 0.07 0.01 0.03 0.13 0.14 0.12 0.11 0.08 0.006
hsa-miR-196b 0.00 0.07 0.00 0.12 0.18 0.09 0.11 0.15 0.008
hsa-miR-454-5p 0.00 0.00 0.07 0.10 0.18 0.22 0.18 0.11 0.008
hsa-miR-1914-3p 0.18 0.10 0.25 0.28 0.45 0.33 0.47 0.35 0.019
hsa-miR-548c-3p 0.00 0.00 0.00 0.13 0.13 0.02 0.06 0.08 0.025
hsa-miR-767-3p 0.18 0.19 0.19 0.20 0.25 0.27 0.25 0.21 0.033
hsa-miR-575 0.31 0.32 0.32 0.34 0.48 0.37 0.47 0.49 0.034
hsa-miR-29c* 0.04 0.08 0.01 0.11 0.26 0.09 0.19 0.15 0.035
hsa-miR-92a 0.75 0.74 0.73 0.74 0.83 0.80 0.81 0.79 0.039
hsa-miR-483-5p 0.31 0.25 0.42 0.41 0.43 0.45 0.52 0.43 0.040
hsa-miR-22 0.74 0.79 0.68 0.74 0.99 0.92 0.92 0.88 0.045
hsa-miR-335-3p 0.06 0.18 0.13 0.17 0.22 0.22 0.20 0.17 0.049
*Passenger strand.
MiR-16–normalized signal intensity levels of miRNA detected on the microarray. 
Statistical differences between groups (N vs. MM) were calculated by two-tailed t test.
MM, malignant mesothelioma; miRNA, MicroRNAs.
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DISCUSSION
Since the discovery of tumor-specific miRNAs in the 
plasma of leukemia patients,13 numerous studies have linked 
changes in circulating miRNAs to the presence of cancer.17 
Most of these studies used miRNA profiles derived from 
tumors to preselect miRNAs for screening. To identify poten-
tial miRNA biomarkers for MM, and to avoid bias in our 
screening, we profiled the miRNA content of plasma from 
MM patients and compared it with that of normal healthy 
controls. Consistent with previous reports, almost all the 
miRNA species detected were common to samples from 
patients and controls,11,21,22 supporting the idea that circulat-
ing miRNAs have an important function in homeostasis and 
are released by cells of the circulatory system.21 Moreover, 
the most abundant miRNAs were the same in patients and 
controls, and although we detected more than 200 distinct 
miRNA species, just two dozen account for more than 90% 
of the miRNA content of plasma (Fig. 1), suggesting that any 
changes in circulating miRNAs are likely to be found in the 
rarer species.
FIGURE 2.  RT-qPCR validation reveals significant differences in miRNAs in plasma/serum from MM patients and controls. Levels 
of candidate miRNAs measured in plasma/serum were normalized to miR-16 expression, and their relative expression as compared 
with the average level in the control samples was calculated using the 2–ΔΔCq method. In the New South Wales test cohort miR-
625-3p level was significantly elevated in the plasma of 15 MM patients, whereas both miR-29c* and miR-92a showed a trend 
toward higher levels in patients without reaching statistical significance (A). MiR-625-3p level was also significantly elevated in 30 
MM patients of the independent  validation cohort (C). The Tukey box plots have median values represented by the line within 
the boxes and the lower and upper limits of the boxes denote the 25th and 75th percentile. ROC curve analyses of plasma miR-
625-3p levels for discrimination of MM in the test (B) and validation (D) cohort, respectively. *p < 0.05 (two-tailed t test). qPCR, 
quantitative polymerase chain reaction; miRNA, MicroRNAs; MM, maligant mesothelioma; ROC, receiver operating characteristic.
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So far, a limited number of studies have investigated 
miRNA expression in MM. Busacca et al.25 compared two 
MM cell lines with immortalized mesothelial cells using 
microarrays, whereas Guled et al.27 compared miRNA 
expression in different histopathological subtypes of MM 
with miRNAs in normal pericardium. The last approach 
identified a number of miRNAs related to MM and its his-
topathological subtypes. Most recently, miRNA profiles of 
MM cell lines were compared with those in normal human 
mesothelial cells, revealing strong up-regulation of the onco-
genic miR-17-92 cluster and its paralogs.23 When compar-
ing these three profiling studies, almost no overlap of the 
specific MM-associated miRNAs was noted (Supplemental 
Data Table 3, Supplemental Digital Content 3, http://links.
lww.com/JTO/A286) and this may well be the consequence 
of different profiling approaches (including normalization 
techniques) and different control samples.
The selection of a control population is an important 
consideration for studies of potential biomarkers in MM 
patients. Although we used healthy controls in our initial dis-
covery phase, individuals with documented asbestos exposure 
are generally regarded a better control group. However, there 
is evidence to suggest that many people in Australia, a country 
with unparalleled presence of asbestos in the built environ-
ment, are either unknowingly exposed or are exposed to low-
level asbestos in a nonoccupational setting.31,32 Consequently, 
we assume that this phenomenon must also have translated 
into our control series. As even low levels of exposure to 
asbestos can elicit mesothelioma, it is difficult to define 
“healthy” subjects. Nevertheless, a formal comparison of cir-
culating miRNA levels in MM patients with those in individu-
als with a documented history of asbestos exposure remains 
an important next step.
The use of miRNAs preselected by profiling of cell 
lines or tumor tissue to detect changes in plasma miRNAs is 
based on the assumption that changes in circulating miRNAs 
derive solely from changes in the expression of miRNAs in the 
tumor. This strategy is unlikely to identify miRNAs present 
at reduced levels in plasma. As the miRNA profile in serum 
is also thought to reflect miRNAs predominantly released by 
blood cells rather than tumor,11,21 changes in miRNA levels 
in serum and other fluids may reflect a systemic response to 
the presence of a tumor, rather than simply being released 
by tumors. Several studies have demonstrated an association 
between reduced serum levels of particular miRNAs and the 
presence of tumor33,34 or other conditions.35–37 Reduced levels 
of miRNAs in general (and specific miRNAs in particular) 
have been shown in a number of tumors, including MM.24,26,29 
Although likely to have important biological consequences, 
low levels of (down-regulated) miRNAs are not ideal as a 
tumor-derived biomarker in plasma/serum.38,39
Reduced levels of miR-29c* were associated with 
poor prognosis, and loss of miR-31 expression was associ-
ated with deletion at 9p21, a frequently observed mutation in 
MM 40. Re-expression of either miR-29c* or miR-31 was able 
to attenuate proliferation, migration, and invasion of MM in 
vitro, suggesting a role for these miRNAs as potential tumor-
suppressor genes.28,29
The trend toward higher levels of miR-92a in plasma 
from MM patients is in line with results from studies of 
colorectal and ovarian carcinoma, which reported higher miR-
92a in patients.14–16 They are also consistent with findings of 
a recent study of miRNA expression profiles in MM, which 
found miR-92a and others of the miR-17-92 cluster to be 
significantly higher in tumor cell lines when compared with 
immortalized mesothelial lines.23
Most recently, the down-regulation of miR-126 in MM 
tumor biopsies has been reported.30 In addition, it was sug-
gested that reduced levels of miR-126 in plasma of patients 
were associated with elevated mesothelin levels and increased 
MM risk. However, we were unable to observe any difference 
in plasma miR-126 levels between patients and controls, and 
more evidence is needed to establish a causal relationship 
between miR-126 levels and the diagnosis of MM.
Our finding that miR-625-3p is present at significantly 
higher levels in plasma and serum of MM patients is the 
first such report of elevated levels of a circulating miRNA 
with potential value as a biomarker for MM. This miRNA 
is yet to be functionally characterized, although its comple-
ment miR-625-5p was identified in genome-wide screens.41 
Identification of putative targets with microscan, targetscan, 
or other algorithms has revealed multiple candidates, and we 
are currently determining the functional significance of miR-
625-3p up-regulation in MM.
Regardless of their origin, circulating miRNAs have 
great potential to serve as new biomarkers.17 In the pres-
ent study, we have identified a previously uncharacterized 
miRNA— miR-625-3p—which is elevated in plasma or 
serum from MM patients and up-regulated in archival tumor 
samples. Taken together, these data from two independent 
series of patients suggest that miR-625-3p represents a prom-
ising biomarker for MM.
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FIGURE 3. Expression of plasma miRNA candidates in 
MM tumor samples. Levels of miRNAs were normalized to 
RNU6B and are expressed relative to the levels in normal 
pericardial tissue as calculated using the 2–ΔΔCq method. Solid 
lines indicate ± twofold changes in tumor as compared with 
normal control samples. *p < 0.05 (two-tailed t test). miRNA, 
MicroRNAs; MM, maligant mesothelioma.
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